Moving towards dose individualization of tyrosine kinase inhibitors
- 14 September 2010
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 37 (4), 251-260
- https://doi.org/10.1016/j.ctrv.2010.08.006
Abstract
No abstract availableKeywords
This publication has 137 references indexed in Scilit:
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological propertiesBritish Journal of Pharmacology, 2009
- Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the TreatmentClinical Cancer Research, 2009
- Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib FailureClinical Cancer Research, 2009
- Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and AdultsClinical Cancer Research, 2008
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemiaBlood, 2008
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2Cancer Research, 2008
- Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid TumorsClinical Cancer Research, 2007
- Population pharmacokinetics of imatinib and the role of α1‐acid glycoproteinBritish Journal of Clinical Pharmacology, 2006
- Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancerBritish Journal of Cancer, 2006
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005